|
| Study ID | Setting | Study drugs | Phase | Status |
|
| NCT02715804 | Metastatic PDAC
(I line—HA high pts) | Nab-P + GEM ± PEGPH20 | III rand | Recruiting |
| NCT02923921 | Metastatic PDAC (II line) | FOLFOX ± AM0010 | III rand | Recruiting |
| NCT02436668 | Metastatic (I line) | Nab-P + GEM ± ibrutinib | II-III rand | Active, not recruiting |
| NCT02030860 | Resectable | Nab-P + GEM ± Paricalcitol | II rand | Active, not recruiting |
| NCT02243371 | Advanced | GVAX + CY + CRS-207 ± Nivolumab | II rand | Active, not recruiting |
| NCT03006302 | Metastatic | Epacadostat + Pembrolizumab + CRS-207 ± CY/GVAX | II rand | Recruiting |
| NCT02648282 | Locally advanced | CY, pembrolizumab, GVAX, and SBRT | II | Recruiting |
| NCT01088789 | Resected | Boost vaccinations of pancreatic tumor cell vaccine | II | Recruiting |
| NCT02826486 | Metastatic | BL-8040 + Pembrolizumab | II | Active, not recruiting |
| NCT03432676 | Advanced | IDO-1 inhibitor + Epacadostat + Pembrolizumab in PDAC with CIS/HRD | II | Not yet recruiting |
| NCT02910882 | Localized, unresectable | PEGPH20 + GEM + radiotherapy | II | Active, not recruiting |
| NCT02451982 | Resectable | GVAX + CY ± Nivolumab | I-II rand | Recruiting |
| NCT03193190 | Metastatic | Atezolizumab + Cobimetinib or Atezolizumab + PEGPH20 or Atezolizumab + BL-8040 | I-II rand | Recruiting |
| NCT02210559 | Locally advanced | GEM + Nab-P ± FG-3019 | I-II rand | Active, not recruiting |
| NCT02311361 | Metastatic | Tremelimumab and/or Durvalumab + radiation therapy | I-II | Recruiting |
| NCT02583477 | Metastatic | Durvalumab | I-II | Active, not recruiting |
| NCT02305186 | Resectable | Pembrolizumab | I-II | Recruiting |
| NCT02077881 | Metastatic | IDO Inhibitor + Nab-P + GEM | I-II | Recruiting |
| NCT02562898 | Metastatic | Ibrutinib + Nab-P + GEM | I-II | Active, not recruiting |
| NCT02529579 | Advanced | iAPA-DC/CTL + GEM | I-II | Recruiting |
| NCT03180437 | Resectable/advanced/metastatic | γδ T-cell | I-II | Recruiting |
| NCT02311361 | Unresectable | Tremelimumab and/or MEDI4736 + radiation therapy+ | I-II | Recruiting |
| NCT03451773 | Advanced | M7824 + GEM | I-II | Recruiting |
| NCT02713529 | Advanced | AMG 820 + Pembrolizumab | I-II | Active, not recruiting |
| NCT02807844 | Metastatic | MCS110 + Spartalizumab | I-II | Recruiting |
| NCT02929797 | Locally advanced | GEM ± CD8 + NKG2D + AKT cell | I rand | Recruiting |
| NCT03519308 | Resectable | Nivolumab + Paricalcitol | I | Recruiting |
| NCT02559674 | Metastatic | ALT-803 + Nab-P + GEM | I | Active, not recruiting |
| NCT02588443 | Resectable | RO7009789 alone or RO7009789 + Nab-P + GEM ➔ RO7009789 + Nab-P + GEM | I | Recruiting |
| NCT02345408 | Advanced | CCX872-B | I | Active, not recruiting |
| NCT02550327 | Advanced | Nab-P + GEM + Cisplatin + Anakinra | I | Recruiting |
| NCT02930902 | Resectable | Pembrolizumab + Paricalcitol ± Nab-P + GEM | I | Recruiting |
| NCT02868632 | Locally advanced | MEDI4736 + SBRT or Tremelimumab + SBRT or MEDI4736 + Tremelimumab + SBRT | I | Recruiting |
| NCT01473940 | Metastatic | Ipilimumab + GEM | I | Active, not recruiting |
| NCT02777710 | Metastatic | Durvalumab + Pexidartinib | I | Recruiting |
| NCT02345408 | Unresectable | CCX872-B | I | Active, not recruiting |
| NCT02045589 | Advanced | VCN-01 + Nab-P + GEM | I | Active, not recruiting |
| NCT03481920 | Advanced or locally advanced | PEGPH20 + Avelumab | I | Recruiting |
| NCT02734160 | Metastatic | Galunisertib + Durvalumab | I | Recruiting |
|
